PTPI
Petros Pharmaceuticals, Inc.
Next earnings ≈ Aug 12, 2026 · est. from filing cadence
$0.01
▲ 0.00%$0.01▼ -78.57%
over 1Y
L $0.01EODHDH $0.04
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W+1.7%
1M+0.0%
3M+0.0%
YTD-25.0%
1Y-78.6%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Strong net margin (37.4%); but revenue fell -12.2% YoY.
Petros Pharmaceuticals, Inc. shows $5.11M in FY2024 revenue (-12.2% YoY), a 37.4% net margin, and 66.7% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $7.81M | $5.99M | $5.82M | $5.11M | — |
| Gross profit | $6.21M | $3.70M | $4.19M | $3.90M | — |
| Operating income | -$18.0M | -$19.9M | -$13.6M | -$4.63M | -$4.64M |
| Net income | -$8.99M | -$20.0M | -$8.16M | -$14.3M | $1.91M |
| Diluted EPS | -$8.25 | -$9.68 | -$6.35 | -$83.47 | -$1.56 |
| Net margin | -115.0% | -334.4% | -140.2% | -280.1% | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$2.29M
EV / EBITDA—
EV / Sales0.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield752.7%
FCF yield-2658.7%
Quality & risk
ROIC (est.)-36.5%
Free cash flow-$6.76M
Total debt$7.18M
Net cash-$2.04M
Altman Z-Score-31.42 distress
Piotroski F-Score6/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-20.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2026-03-31). Worth a closer look.
- 8-K Officer / director change2026-06-18
- 8-K Officer / director change2026-06-05
- 10-Q Quarterly report2026-05-13
- 10-K Annual report2026-04-15
- NT 10-K Late filing notice2026-03-31
- 8-K Officer / director change2026-01-02
- 10-Q Quarterly report2025-11-13
- 8-K Delisting notice2025-11-07
- 8-K Auditor change2025-09-05
Recent filings
all on EDGAR ↗3Period ending 2026-06-182026-06-25open ↗8-KPeriod ending 2026-06-182026-06-18open ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-052026-06-05open ↗4Period ending 2026-06-052026-06-05open ↗4Period ending 2026-06-052026-06-05open ↗8-KPeriod ending 2026-06-052026-06-05open ↗10-QPeriod ending 2026-03-312026-05-13open ↗10-KPeriod ending 2025-12-312026-04-15open ↗NT 10-KPeriod ending 2025-12-312026-03-31open ↗SCHEDULE 13G/AFiling2026-02-17open ↗4Period ending 2026-01-022026-01-06open ↗
Frequently asked
- Is Petros Pharmaceuticals, Inc. (PTPI) a buy?
- PTPI currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Strong net margin (37.4%); but revenue fell -12.2% YoY.
- What is Petros Pharmaceuticals, Inc.'s quality score?
- PTPI scores 74.15686274509802/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001815903, latest 10-Q filed 2026-05-13) · EODHD · as of 6/22/2026, 10:54:37 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.